*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.
Axsome Therapeutics (AXSM) is poised for its upcoming earnings report on November 3, 2025, with a market cap of approximately $6.57 billion, reflecting investor confidence in its innovative pipeline. Despite the absence of recent news, the company's strategic focus on developing novel therapies for central nervous system disorders continues to capture market interest. Analysts anticipate flat earnings per share (EPS) at $0.00, aligning with the whisper number, while revenue is expected to reach $162.43 million. This revenue estimate underscores Axsome's potential to maintain its growth trajectory, driven by the successful commercialization of its key products. As the market awaits the earnings release, the alignment of the EPS estimate with the whisper number suggests that investors are cautiously optimistic about Axsome's ability to meet expectations, while any deviation in revenue could provide further insight into the company's operational momentum.
Axsome Therapeutics, Inc., a biopharmaceutical company, is dedicated to developing new therapies for central nervous system (CNS) disorders in the United States. The company is headquartered in New York, New York.
Website: https://www.axsome.com
Average Sentiment Score:
Overall Sentiment: